ALDX - Aldeyra Therapeutics Stock Price, News & Analysis

$6.35 0.25 (4.10 %)
(As of 11/23/2017 08:19 AM ET)
Previous Close$6.10
Today's Range$6.00 - $6.45
52-Week Range$3.80 - $11.90
Volume93,500 shs
Average Volume293,518 shs
Market Capitalization$116.62 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52

About Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALDX
CUSIPN/A

Debt

Debt-to-Equity Ratio0.02%
Current Ratio20.35%
Quick Ratio20.35%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.40 per share
Price / Book2.65

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.40)
Net Income$-18,690,000.00
Net MarginsN/A
Return on Equity-67.43%
Return on Assets-60.54%

Miscellaneous

Employees11
Outstanding Shares19,120,000

Frequently Asked Questions for Aldeyra Therapeutics (NASDAQ:ALDX)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) posted its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.09. View Aldeyra Therapeutics' Earnings History.

Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2017?

5 Wall Street analysts have issued 12-month price objectives for Aldeyra Therapeutics' stock. Their forecasts range from $14.00 to $27.00. On average, they expect Aldeyra Therapeutics' stock price to reach $19.40 in the next twelve months. View Analyst Ratings for Aldeyra Therapeutics.

What are Wall Street analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (11/14/2017)
  • 2. Cowen and Company analysts commented, "On its 4Q call, ALDX announced the Feb start of the planned ADX-102 Ph2b allergic." (3/31/2017)

Who are some of Aldeyra Therapeutics' key competitors?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:

  • Todd C. Brady M.D. Ph.D., President, Chief Executive Officer, Director (Age 46)
  • Stephen J. Tulipano CPA, Chief Financial Officer, Treasurer (Age 55)
  • Scott L Young, Chief Operating Officer (Age 51)
  • David J. Clark M.D., Chief Medical Officer
  • Ben Bronstein M.D., Director (Age 65)
  • Jesse I. Treu Ph.D., Director (Age 70)
  • Richard H. Douglas Ph.D., Independent Director (Age 64)
  • Martin J. Joyce, Independent Director (Age 61)
  • Gary M. Phillips M.D., Independent Director (Age 51)

Who owns Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (16.14%), Sphera Funds Management LTD. (5.61%) and Bank of New York Mellon Corp (0.10%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Who bought Aldeyra Therapeutics stock? Who is buying Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Sphera Funds Management LTD. and Bank of New York Mellon Corp. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy Aldeyra Therapeutics stock?

Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of Aldeyra Therapeutics stock can currently be purchased for approximately $6.35.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $116.62 million. The biotechnology company earns $-18,690,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Aldeyra Therapeutics employs 11 workers across the globe.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]


MarketBeat Community Rating for Aldeyra Therapeutics (ALDX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Aldeyra Therapeutics (NASDAQ:ALDX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.40 (205.51% upside)

Consensus Price Target History for Aldeyra Therapeutics (NASDAQ:ALDX)

Price Target History for Aldeyra Therapeutics (NASDAQ:ALDX)

Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/24/2017Cantor FitzgeraldInitiated CoverageOverweight$22.00N/AView Rating Details
9/14/2017Cowen and CompanyReiterated RatingOutperform$9.00 -> $14.00HighView Rating Details
9/13/2017Canaccord GenuityReiterated RatingBuy -> Buy$12.00 -> $27.00MediumView Rating Details
8/9/2017HC WainwrightSet Price TargetBuy$18.00LowView Rating Details
5/31/2017Stifel NicolausReiterated RatingBuy$16.00MediumView Rating Details
2/29/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Aldeyra Therapeutics (NASDAQ:ALDX)

Earnings by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Earnings History by Quarter for Aldeyra Therapeutics (NASDAQ ALDX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.41)($0.32)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.37)($0.35)ViewListenView Earnings Details
5/15/2017Q1 2017($0.33)($0.37)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.66)($0.36)ViewN/AView Earnings Details
11/14/2016Q316($0.39)($0.38)ViewN/AView Earnings Details
8/10/2016Q216($0.44)($0.41)ViewListenView Earnings Details
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
Current Year EPS Consensus Estimate: $-1.39 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS

Dividends

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aldeyra Therapeutics (NASDAQ ALDX)

Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 40.06%
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ ALDX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017Life Sciences Maste PerceptiveMajor ShareholderBuy200,000$7.25$1,450,000.00View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy296,007$4.60$1,361,632.20View SEC Filing  
2/17/2017Martin Joseph JoyceDirectorBuy4,444$4.50$19,998.00View SEC Filing  
2/17/2017Stephen J TulipanoCFOBuy3,333$4.50$14,998.50View SEC Filing  
2/17/2017Todd C BradyInsiderBuy22,223$4.50$100,003.50View SEC Filing  
2/14/2017Perceptive Advisors LlcMajor ShareholderBuy893,025$4.50$4,018,612.50View SEC Filing  
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aldeyra Therapeutics (NASDAQ ALDX)

Source:
DateHeadline
Aldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Buy" by AnalystsAldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 20 at 1:52 AM
FY2017 Earnings Estimate for Aldeyra Therapeutics, Inc. (ALDX) Issued By Cantor FitzgeraldFY2017 Earnings Estimate for Aldeyra Therapeutics, Inc. (ALDX) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 15 at 7:32 AM
Aldeyra Therapeutics, Inc. (ALDX) Stock Rating Upgraded by Zacks Investment ResearchAldeyra Therapeutics, Inc. (ALDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 14 at 8:28 PM
Aldeyra Therapeutics (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 2:31 PM
Aldeyra Therapeutics, Inc. (ALDX) Releases Quarterly  Earnings Results, Beats Expectations By $0.09 EPSAldeyra Therapeutics, Inc. (ALDX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Aldeyra Therapeutics Announces Third Quarter 2017 Financial ResultsAldeyra Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 4:44 PM
Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?
finance.yahoo.com - November 9 at 4:44 PM
Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare ConferenceAldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 7 at 5:19 PM
Aldeyra Therapeutics, Inc. (ALDX) Scheduled to Post Earnings on MondayAldeyra Therapeutics, Inc. (ALDX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial ResultsAldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 4:08 PM
Cantor Fitzgerald Weighs in on Aldeyra Therapeutics, Inc.s FY2017 Earnings (ALDX)Cantor Fitzgerald Weighs in on Aldeyra Therapeutics, Inc.'s FY2017 Earnings (ALDX)
www.americanbankingnews.com - October 27 at 9:44 AM
Aldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUSAldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS
www.streetinsider.com - October 26 at 8:43 PM
Aldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Hold" by BrokeragesAldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 26 at 1:34 AM
Aldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS - StreetInsider.comAldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS - StreetInsider.com
www.streetinsider.com - October 25 at 9:36 PM
Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual MeetingAldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
finance.yahoo.com - October 25 at 4:34 PM
UPDATE: Cantor Fitzgerald Starts Aldeyra Therapeutics (ALDX) at Overweight - StreetInsider.comUPDATE: Cantor Fitzgerald Starts Aldeyra Therapeutics (ALDX) at Overweight - StreetInsider.com
www.streetinsider.com - October 24 at 10:15 PM
Aldeyra Therapeutics (ALDX) Reports Datafor Aldehyde Sequestration as Potential Therapeutic Approach in Succinic ... - StreetInsider.comAldeyra Therapeutics (ALDX) Reports Datafor Aldehyde Sequestration as Potential Therapeutic Approach in Succinic ... - StreetInsider.com
www.streetinsider.com - October 24 at 5:06 PM
Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual MeetingAldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting
finance.yahoo.com - October 24 at 5:06 PM
Cantor Fitzgerald Initiates Coverage on Aldeyra Therapeutics, Inc. (ALDX)Cantor Fitzgerald Initiates Coverage on Aldeyra Therapeutics, Inc. (ALDX)
www.americanbankingnews.com - October 24 at 4:50 PM
Head-To-Head Analysis: Aldeyra Therapeutics (ALDX) vs. Its CompetitorsHead-To-Head Analysis: Aldeyra Therapeutics (ALDX) vs. Its Competitors
www.americanbankingnews.com - October 24 at 10:44 AM
Financial Review: Aldeyra Therapeutics (ALDX) and Its CompetitorsFinancial Review: Aldeyra Therapeutics (ALDX) and Its Competitors
www.americanbankingnews.com - October 18 at 2:24 PM
Aldeyra Therapeutics, Inc. (ALDX) Short Interest Down 45.3% in SeptemberAldeyra Therapeutics, Inc. (ALDX) Short Interest Down 45.3% in September
www.americanbankingnews.com - October 14 at 2:04 AM
Aldeyra Therapeutics, Inc. (ALDX) Downgraded to Sell at Zacks Investment ResearchAldeyra Therapeutics, Inc. (ALDX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - October 10 at 8:56 PM
Aldeyra Therapeutics Announces New Data at 2017 Research & Development DayAldeyra Therapeutics Announces New Data at 2017 Research & Development Day
finance.yahoo.com - October 10 at 5:07 PM
Aldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per ShareAldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - October 5 at 6:18 PM
Aldeyra Therapeutics (ALDX) Presents Novel Data on Efficacy of ADX-102 in Model of Succinic Semialdehyde ... - StreetInsider.comAldeyra Therapeutics (ALDX) Presents Novel Data on Efficacy of ADX-102 in Model of Succinic Semialdehyde ... - StreetInsider.com
www.streetinsider.com - October 5 at 1:07 PM
Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual MeetingAldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting
finance.yahoo.com - October 5 at 1:07 PM
Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?
finance.yahoo.com - October 2 at 8:35 PM
/C O R R E C T I O N -- Aldeyra Therapeutics, Inc.//C O R R E C T I O N -- Aldeyra Therapeutics, Inc./
finance.yahoo.com - October 2 at 3:33 PM
Aldeyra Therapeutics, Inc. (ALDX) Receives Average Rating of "Buy" from BrokeragesAldeyra Therapeutics, Inc. (ALDX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 3:14 AM
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to ... - PR Newswire (press release)Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to ... - PR Newswire (press release)
www.prnewswire.com - September 23 at 8:50 PM
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional SharesAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - September 22 at 2:47 PM
Life Sciences Maste Perceptive Purchases 200,000 Shares of Aldeyra Therapeutics, Inc. (ALDX) StockLife Sciences Maste Perceptive Purchases 200,000 Shares of Aldeyra Therapeutics, Inc. (ALDX) Stock
www.americanbankingnews.com - September 21 at 10:26 AM
Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare ConferenceAldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 3:39 PM
Mid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations - BenzingaMid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations - Benzinga
www.benzinga.com - September 19 at 3:44 PM
Aldeyra Therapeutics (ALDX) Prices 3.45M Common Stock Offering at $7.25/Share - StreetInsider.comAldeyra Therapeutics (ALDX) Prices 3.45M Common Stock Offering at $7.25/Share - StreetInsider.com
www.streetinsider.com - September 19 at 3:43 PM
Aldeyra Therapeutics: Secondary Offering Clears Key Overhang - Seeking AlphaAldeyra Therapeutics: Secondary Offering Clears Key Overhang - Seeking Alpha
seekingalpha.com - September 19 at 3:43 PM
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common StockAldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 19 at 3:43 PM
Aldeyra Therapeutics: Transitioning Into A Promising Late-Stage Story - Seeking AlphaAldeyra Therapeutics: Transitioning Into A Promising Late-Stage Story - Seeking Alpha
seekingalpha.com - September 18 at 9:10 PM
Aldeyra Finally Gets The Recognition It Deserves - Seeking AlphaAldeyra Finally Gets The Recognition It Deserves - Seeking Alpha
seekingalpha.com - September 18 at 9:10 PM
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common StockAldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 18 at 4:08 PM
 Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - September 17 at 12:30 AM
Aldeyra Spikes On Significant Improvements In Midstage Dry Eye Study - Seeking AlphaAldeyra Spikes On 'Significant Improvements' In Midstage Dry Eye Study - Seeking Alpha
seekingalpha.com - September 16 at 3:35 PM
Todays Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead PharmaceuticalsToday's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals
finance.yahoo.com - September 15 at 4:04 PM
Aldeyra Therapeutics (ALDX) "Outperform" Rating Reaffirmed at Cowen and CompanyAldeyra Therapeutics' (ALDX) "Outperform" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - September 14 at 9:08 AM
Pre-Open Stock Movers 09/13: (SNAK) (ALDX) (JWN) Higher; (DCTH) (AMRK) (WDC) Lower (more...)Pre-Open Stock Movers 09/13: (SNAK) (ALDX) (JWN) Higher; (DCTH) (AMRK) (WDC) Lower (more...)
www.streetinsider.com - September 14 at 2:55 AM
Aldeyra Therapeutics (ALDX) Presents On Dry Eye Disease Phase 2a Results - SlideshowAldeyra Therapeutics (ALDX) Presents On Dry Eye Disease Phase 2a Results - Slideshow
seekingalpha.com - September 14 at 2:55 AM
Aldeyra Therapeutics Inc. (ALDX) Jumped To A 5-Month High On Study ResultsAldeyra Therapeutics Inc. (ALDX) Jumped To A 5-Month High On Study Results
www.rttnews.com - September 13 at 4:53 PM
Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in SessionAldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
finance.yahoo.com - September 13 at 4:53 PM
Aldeyra Therapeutics, Inc. (ALDX) Stock Rating Reaffirmed by Canaccord GenuityAldeyra Therapeutics, Inc. (ALDX) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 13 at 8:36 AM

Social Media

Financials

Chart

Aldeyra Therapeutics (NASDAQ ALDX) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.